VistaGen Therapeutics is a
San Francisco-based biotechnology company that focuses on human stem cell
technology for the purposes of drug rescue, predictive toxicology, and drug
metabolism screening. The company was founded in 1998 and has spent the last 16
years establishing its reputation as an expert in human pluripotent stem cell
(hPSC) technology.
VistaGen Therapeutics’ drug
rescue efforts involve combining its hPSC technology with the most up-to-date
medicinal chemistry to generate new chemical variants of drug candidates that
were abandoned by biotechnology or pharmaceutical companies before the market
approval stage.
The drug candidates in which
VistaGen is interested include those that were abandoned because of concerns
about their effect on the heart and liver. VistaGen believes it can work with
these discontinued drug candidates to cost effectively generate new,
proprietary variants with reduced toxicity. The company’s end goal is to
generate a pipeline of Drug Rescue Variants™ and sell them to biotechnology and
pharmaceutical companies so that they can be further developed, approved, and
sold commercially.
VistaGen Therapeutics is
accomplishing its goals through the use of its hPSC technology platform, called
Human Clinical Trials in a Test Tube™. The technology allows VistaGen to assess
the Drug Rescue Variants’ heart and liver safety profiles.
Though there are other
technologies like this on the market, Human Clinical Trials in a Test Tube™ is
unique because it allows VistaGen to perform this task with greater speed and
precision than conventional testing technology. Often times, companies spend
decades and millions of dollars in drug candidates that only result in failure.
VistaGen’s model is designed to leverage third-party investments, speed up the
testing process, and recycle candidates that may have only been a few steps shy
of being successful.
VistaGen’s research
initiatives extend beyond its laboratories. In April 2014, the company
announced that it became a member of the Cardiac Safety Research Consortium, an
organization that supports research into the evaluation of cardiac safety of
medical products. VistaGen is committed to staying at the cutting edge of
cardiac safety, given that it is the lynchpin for the success of its
proprietary drug candidates.
For more information, please
visit www.vistagen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
